川宁生物
(301301)
| 流通市值：63.88亿 | | | 总市值：230.59亿 |
| 流通股本：6.18亿 | | | 总股本：22.30亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 747,734,814.73 | 808,484,774.9 | 952,641,981.24 | 1,088,331,674.61 |
| 交易性金融资产 | - | 4,354.45 | 190,326,700 | - |
| 应收票据及应收账款 | 971,765,969.39 | 1,028,499,781.23 | 978,368,112.66 | 939,301,959.14 |
| 应收账款 | 971,765,969.39 | 1,028,499,781.23 | 978,368,112.66 | 939,301,959.14 |
| 应收款项融资 | 564,084,801.71 | 797,180,216.88 | 960,457,749.57 | 632,971,958.55 |
| 预付款项 | 490,580,029.13 | 108,203,249.76 | 104,796,966.28 | 89,111,515.36 |
| 其他应收款合计 | 860,966.96 | 1,246,915.16 | 863,899.5 | 531,437.96 |
| 存货 | 1,071,619,189.64 | 1,099,753,774.36 | 1,166,767,035.51 | 1,342,070,643.16 |
| 其他流动资产 | 175,035,245.33 | 73,108,206.24 | 62,156,479.8 | 51,904,684.76 |
| 流动资产合计 | 4,021,681,016.89 | 3,916,481,272.98 | 4,416,378,924.56 | 4,144,223,873.54 |
| 非流动资产: | | | | |
| 长期股权投资 | 146,821,327.94 | 37,102,039.87 | 37,895,227.74 | 15,804,416.14 |
| 其他权益工具投资 | 24,883,131.36 | 24,883,131.36 | 24,883,131.36 | 24,883,131.36 |
| 其他非流动金融资产 | 30,000,000 | 30,000,000 | 30,000,000 | 30,000,000 |
| 固定资产 | 5,001,762,901.7 | 5,041,928,525.73 | 5,145,153,895.18 | 5,274,478,102.29 |
| 在建工程 | 330,324,789.2 | 329,427,851.73 | 306,932,821.22 | 285,310,350.24 |
| 使用权资产 | 473,316,443.33 | 477,730,861.28 | 481,591,643.3 | 485,986,521.14 |
| 无形资产 | 233,981,581.63 | 238,961,367.43 | 231,042,455.17 | 235,834,585.17 |
| 开发支出 | 1,000,000 | 1,000,000 | 1,000,000 | - |
| 商誉 | 1,365,974 | 1,365,974 | 1,365,974 | 1,365,974 |
| 长期待摊费用 | 878,253.01 | 1,097,816.26 | 1,317,379.51 | 1,536,942.76 |
| 递延所得税资产 | 23,660,361.78 | 23,928,973.17 | 22,311,722.61 | 20,902,576.94 |
| 其他非流动资产 | 41,101,900.55 | 35,396,478.78 | 32,670,082.18 | 33,253,487.59 |
| 非流动资产合计 | 6,309,096,664.5 | 6,242,823,019.61 | 6,316,164,332.27 | 6,409,356,087.63 |
| 资产总计 | 10,330,777,681.39 | 10,159,304,292.59 | 10,732,543,256.83 | 10,553,579,961.17 |
| 流动负债: | | | | |
| 短期借款 | 360,139,102.22 | 210,138,694.44 | 210,152,563.9 | 210,152,563.9 |
| 交易性金融负债 | 226,400 | - | - | - |
| 应付票据及应付账款 | 655,307,626.43 | 663,543,228.39 | 803,122,700.27 | 895,435,078.43 |
| 其中：应付票据 | - | - | 150,000,000 | 150,000,000 |
| 应付账款 | 655,307,626.43 | 663,543,228.39 | 653,122,700.27 | 745,435,078.43 |
| 合同负债 | 18,628,495.65 | 46,630,525.73 | 27,011,436.35 | 66,818,283.92 |
| 应付职工薪酬 | 28,848,214.88 | 27,617,787.75 | 27,320,395.74 | 36,976,800.22 |
| 应交税费 | 92,634,952.12 | 88,171,712.11 | 132,357,282.05 | 103,010,765.84 |
| 其他应付款合计 | 40,157,996.36 | 31,889,701.9 | 28,849,180.84 | 12,540,823.65 |
| 一年内到期的非流动负债 | 402,486,073.27 | 737,627,814.42 | 740,577,942 | 617,055,432.24 |
| 其他流动负债 | 202,635,778.06 | 5,709,046.79 | 2,676,260.94 | 5,545,141.46 |
| 流动负债合计 | 1,801,064,638.99 | 1,811,328,511.53 | 1,972,067,762.09 | 1,947,534,889.66 |
| 非流动负债: | | | | |
| 长期借款 | - | - | 0 | 146,000,000 |
| 租赁负债 | 464,446,911.53 | 459,840,638.01 | 455,671,460.69 | 451,123,131.01 |
| 预计负债 | 2,824,429.57 | 2,999,965.19 | 3,042,782.82 | - |
| 递延收益 | 110,920,029.46 | 98,068,040.25 | 94,564,194.16 | 92,506,096.57 |
| 递延所得税负债 | 11,721.32 | 86,231.48 | - | - |
| 非流动负债合计 | 578,203,091.88 | 560,994,874.93 | 553,278,437.67 | 689,629,227.58 |
| 负债合计 | 2,379,267,730.87 | 2,372,323,386.46 | 2,525,346,199.76 | 2,637,164,117.24 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 2,230,085,000 | 2,230,085,000 | 2,227,160,000 | 2,227,160,000 |
| 资本公积 | 3,299,672,495.23 | 3,298,671,736.44 | 3,286,849,204.19 | 3,284,274,587.58 |
| 其他综合收益 | -99,338.34 | -99,338.34 | -99,338.34 | -99,338.34 |
| 盈余公积 | 325,319,096.72 | 325,319,096.72 | 325,319,096.72 | 325,319,096.72 |
| 未分配利润 | 2,070,993,092.53 | 1,914,458,192.58 | 2,349,151,220.87 | 2,060,932,688.15 |
| 归属于母公司股东权益合计 | 7,925,970,346.14 | 7,768,434,687.4 | 8,188,380,183.44 | 7,897,587,034.11 |
| 少数股东权益 | 25,539,604.38 | 18,546,218.73 | 18,816,873.63 | 18,828,809.82 |
| 股东权益合计 | 7,951,509,950.52 | 7,786,980,906.13 | 8,207,197,057.07 | 7,916,415,843.93 |
| 负债和股东权益合计 | 10,330,777,681.39 | 10,159,304,292.59 | 10,732,543,256.83 | 10,553,579,961.17 |
| 公告日期 | 2025-10-28 | 2025-08-26 | 2025-04-29 | 2025-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |